Bone mineral density thresholds for pharmacological intervention to prevent fractures.
about
Osteoporosis and its managementLow bone mineral density and fracture burden in postmenopausal womenCOPD and osteoporosis: links, risks, and treatment challengesGrowth and Age-Related Abnormalities in Cortical Structure and Fracture Risk.Multisite quantitative ultrasound for the prediction of fractures over 5 years of follow-up: the Canadian Multicentre Osteoporosis Study.Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practiceFracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data.Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 Fifth Korean National Health and Nutrition Examination survey data.Advances in imaging approaches to fracture risk evaluation.Bone quality: an empty term.Cost-effectiveness of preventative therapies for postmenopausal women with osteopeniaHip fracture types in men and women change differently with agePrevention of hip fractures in long-term care: relevance of community-derived data.The assessment of fracture risk.Assessment of fracture risk in women with breast cancer using current vs emerging guidelines.Aromatase inhibitors-induced bone loss in early breast cancer.Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.The evolving role of zoledronic acid in early breast cancerAssessment of individual fracture risk: FRAX and beyond.Increased fracture rate in women with breast cancer: a review of the hidden risk.Structural and mechanical parameters of trabecular bone estimated from in vivo high-resolution magnetic resonance images at 3 tesla field strength.Depression after low-energy fracture in older women predicts future falls: a prospective observational study.Build better bones with exercise: protocol for a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in women with a vertebral fractureComparing the T scores from bone sonometer measurements in Hispanic and non-Hispanic white women.Cortical porosity identifies women with osteopenia at increased risk for forearm fractures.The utility and limitations of FRAX: A US perspective.Bazedoxifene: literature data and clinical evidenceEvaluation of compressive strength index of the femoral neck in Caucasians and chinese.Zoledronic acid infusion for prevention and treatment of osteoporosisBone mineral density status in urolithiasis patients with vitamin D inadequacy followed at a tertiary stone centre.Variations in morphological and biomechanical indices at the distal radius in subjects with identical BMD.Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture.Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study.The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complicationsAlterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study.A comparison of bone density and bone morphology between patients presenting with hip fractures, spinal fractures or a combination of the two.Treatment of osteopenia.Hip structural changes and fracture risk in osteopenia and osteoporosisHow many high risk korean patients with osteopenia could overlook treatment eligibility?
P2860
Q24670075-78CCDB73-941E-4E47-9EC8-F670168B59BFQ24671503-8417284F-862E-47F7-A8BF-9957794AF86DQ26751371-32FF37BD-7C6B-45A9-A4B8-5C289804F946Q26782160-FC8D9C98-CC8F-4063-96DA-88CB6F8A69C8Q30370578-C71C426A-E4D2-4EBD-BAEB-185065EC421AQ30419150-8270DA4C-4F55-4B18-B46D-342783334C62Q30492459-31146809-BCD1-4689-AE50-2DC8159C53DFQ30689651-29C77912-E420-499F-AF7E-82823D981663Q30717217-E78953C0-E83E-4599-A935-735D4AF79186Q31141102-A657DF84-375C-4C20-8C83-4A1D05FE8A5BQ33277096-C5BDBC7A-F498-4E84-9305-AE32EB1A7A95Q33282322-16FA66B8-AF10-4A51-9B3F-7E22B898420DQ33538867-4E5C6A60-18B4-40E3-A614-2EE0C1AFBEE8Q33546626-7310E807-CDE2-41E1-B3A3-10D223987950Q33685092-82DC68C1-27E5-436E-AB71-97682C43BDFFQ33723674-B1E81448-BFC4-4703-B272-207F8554D48DQ33752867-67271DAF-2DF1-43FA-A2CB-A0F21F3F4F07Q33832012-A35EB523-21E3-4FEC-8FCF-C748C822548EQ33915978-DA6D62C6-3E25-49BA-A6F7-FD8EF2C5F279Q33988058-CD65EAB2-8881-4B85-8269-22A536E94219Q34004925-EF869657-7F83-46C7-B7B1-08EA9E1EDF7DQ34015502-661F9568-DB87-413C-BF3C-E6727C15602CQ34068873-B9CB5441-640E-4C79-BA93-D971A954474EQ34135688-4920B160-54DF-4F4E-A361-96C5804565B3Q34138805-89A2F7B7-AFC4-428E-BD15-33A312D3BB33Q34145022-F82598CD-C791-4D30-BF61-01CE05654D5DQ34161186-4169999E-FFB1-41EE-BC7C-196F103010C2Q34213748-E3978B33-0BF0-4264-81A1-E4A54D0ABCC3Q34252375-3FC2F6DB-5A34-46D9-B650-E45E32D9C941Q34345697-9CFFEE45-5B40-4D03-A282-668436BAD16CQ34435990-E7C920F9-5981-4914-A53B-85E9F1C5F0C7Q34482348-CA1835F9-70C4-405B-9349-344EE2AA608AQ34553270-74374BA7-896D-4A19-B812-893644A945DAQ34582203-A31DEB8A-FEA2-4EDC-85B4-18B22D5A401CQ34590994-50CD6637-9646-40D0-BB3F-41ADE1E40F61Q34593182-C451D2DC-25E5-4E21-AD0B-6C8FA82B2FCBQ34595767-0DC837B0-56DB-4B14-9F10-D3420085B97DQ34630644-BC1A0C69-12F8-4CC0-B5C7-55880958955BQ34666484-C11E875A-F910-4E46-AF9B-24E1CE2BA00BQ34785178-4FE464FD-2F64-4EC9-81D4-B44BFB5C4735
P2860
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
@en
type
label
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
@en
prefLabel
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
@en
P2093
P1476
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
@en
P2093
Ethel S Siris
Lois E Wehren
Marc L Berger
Paul D Miller
Thomas A Abbott
Ya-Ting Chen
P304
P356
10.1001/ARCHINTE.164.10.1108
P407
P577
2004-05-01T00:00:00Z